Items where authors include "Pope, A."

Article

Colton, H. orcid.org/0000-0002-3287-4103, Barratt, N., Temperton, N. et al. (34 more authors) (2024) Greater preservation of SARS‐CoV‐2 neutralising antibody responses following the ChAdOx1‐S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients. British Journal of Haematology, 205 (6). pp. 2206-2218. ISSN 0007-1048

James, N. orcid.org/0000-0002-7314-8204, Pirrie, S. orcid.org/0000-0002-2894-2230, Liu, W. orcid.org/0000-0002-6682-2053 et al. (10 more authors) (2024) Image directed redesign of bladder cancer treatment pathways: the BladderPath RCT. Health Technology Assessment, 28 (42). ISSN 1366-5278

Parker, C.C. orcid.org/0000-0001-6512-124X, Petersen, P.M., Cook, A.D. orcid.org/0000-0003-4417-2632 et al. (55 more authors) (2024) Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Annals of Oncology, 35 (7). pp. 656-666. ISSN 0923-7534

Fornacon-Wood, I., Banfill, K., Ahmad, S. et al. (22 more authors) (2023) Impact of the COVID-19 pandemic on outcomes for patients with lung cancer receiving curative-intent radiotherapy in the UK. Clinical Oncology, 35 (10). e593-e600. ISSN 0936-6555

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine. ISSN 1078-8956

Barnes, E. orcid.org/0000-0002-0860-0831, Goodyear, C.S. orcid.org/0000-0001-5926-5941, Willicombe, M. orcid.org/0000-0002-6404-0584 et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nature Medicine, 29 (7). pp. 1760-1774. ISSN 1078-8956

Xiao, M.-Y. orcid.org/0000-0003-1207-5344, Elbaz, D. orcid.org/0000-0002-7631-647X, Gómez-Guijarro, C. orcid.org/0000-0002-4085-9165 et al. (37 more authors) (2023) The hidden side of cosmic star formation at z > 3. Astronomy & Astrophysics, 672. A18. ISSN 0004-6361

James, N.D., Ali, A., Pope, A. et al. (5 more authors) (2022) Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. BJUI Compass, 3 (6). pp. 484-493. ISSN 2688-4526

Gómez-Guijarro, C., Elbaz, D., Xiao, M. et al. (38 more authors) (2022) GOODS-ALMA 2.0 : starbursts in the main sequence reveal compact star formation regulating galaxy evolution prequenching. Astronomy & Astrophysics, 659. A196. ISSN 0004-6361

Gómez-Guijarro, C., Elbaz, D., Xiao, M. et al. (35 more authors) (2022) GOODS-ALMA 2.0 : source catalog, number counts, and prevailing compact sizes in 1.1 mm galaxies. Astronomy & Astrophysics, 658. A43. ISSN 0004-6361

Banfill, K., Croxford, W., Fornacon-Wood, I. et al. (22 more authors) (2022) Changes in the management of patients having radical radiotherapy for lung cancer during the first wave of the COVID-19 pandemic in the UK. Clinical Oncology, 34 (1). pp. 19-27. ISSN 0936-6555

Zhou, L., Elbaz, D., Franco, M. et al. (30 more authors) (2020) GOODS-ALMA: Optically dark ALMA galaxies shed light on a cluster in formation at z = 3.5. Astronomy & Astrophysics, 642. A155. ISSN 0004-6361

Franco, M., Elbaz, D., Bethermin, M. et al. (36 more authors) (2018) GOODS-ALMA: 1.1 mm galaxy survey I. Source catalog and optically dark galaxies. Astronomy and Astrophysics, 620. A152. ISSN 0004-6361

James, N., Pirrie, S., Pope, A. et al. (17 more authors) (2016) TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer. Health Technology Assessment, 20. 53. ISSN 1366-5278

Andronis, L., Goranitis, I., Pirrie, S. et al. (19 more authors) (2016) Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). BJU International. ISSN 1464-4096